Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 10c; Guides In-Line

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.30, $0.10 better than the analyst estimate of $4.20. Revenue for the quarter came in at $932.9 million versus the consensus estimate of $902.46 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2022 EPS of $16.70-$17.71, versus the consensus of $17.09. Jazz Pharmaceuticals sees FY2022 revenue of $3.5-3.7 billion, versus the consensus of $3.6 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Raymond James cuts Delta and JetBlue ratings ahead of Q2 earnings
• Boardwalk REIT reports occupancy near 97%, $306M in 2026 asset sales
• Proto Labs (PRLB) PT Raised to $91 at Benchmark on Meeting and Exceeding Previous Target